KRAS and neoplasm: Conversely, we showed knocking down MTH1 in NSCLC cells with activating KRAS mutations reduces their tumor formation ability and eliminates the highest RAS oncoprotein-expressing subpopulations in the tumor, leading to an overall reduction in ROS levels, as well as Akt signaling [27].